Starting semaglutide at 0.5 mg: the misconception worth clearing up first

Where the 0.5 mg figure comes from, and why it creates confusion

Semaglutide is sold under two brand names in the UK. Ozempic, which carries a starting dose of 0.25 mg rising to 0.5 mg and then 1 mg for blood sugar control, is licensed for type 2 diabetes. Wegovy uses the same active ingredient but at higher doses and for weight management. Its escalation pathway is distinct: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg, and since April 2026, a 7.2 mg pen approved by the MHRA for patients who need or tolerate a higher maintenance dose.

The overlap is the source of the confusion. Someone researching semaglutide online will find plenty of references to 0.5 mg as a starting point, but those references are almost always about Ozempic in a diabetes context. For weight management, 0.5 mg is the second dose, not the first. Jumping to it without the 0.25 mg introductory phase is not how the Wegovy schedule is designed to work, and prescribers follow the licensed pathway for good reason.

The 0.5 mg dose of semaglutide does appear in the Wegovy schedule, it's simply not where the journey starts. Understanding the distinction between the two products is also important if you're considering which treatment fits your situation, and our Wegovy overview covers both products and their licensed uses clearly.

Why the 0.25 mg starting dose exists, and what it's doing in the body

GLP-1 receptor agonists like semaglutide slow the rate at which the stomach empties, increase feelings of fullness, and reduce appetite signals in the brain. These effects are real and, for most people, noticeable fairly quickly. They are also the direct cause of the nausea, queasiness and loose stools that some people experience in the early weeks.

The 0.25 mg dose is low enough that most people's digestive systems adjust to these new signals without significant disruption. It is a tolerability step, not a therapeutic one, the dose at which meaningful weight loss tends to accumulate is higher. Rushing past it doesn't make the medicine work faster; it makes the side-effect profile harder to manage, which is why the evidence and prescribing guidance both argue against starting at a higher dose than 0.25 mg.

The NHS patient information for semaglutide explains this escalation pathway in plain terms and is worth reading before your first pen arrives. If you're also wondering how many doses your semaglutide pen contains, that's a practical detail worth checking before you begin, so you know what to expect from each device. Side effects, when they do occur, are generally most noticeable in the days after a dose increase and tend to settle as the body adjusts. Protein intake, hydration and eating slowly all help, your prescriber can advise on specifics for your situation.

What happens between 0.5 mg and the maintenance dose

After the four-week introductory period at 0.25 mg, most people move to 0.5 mg for another four weeks, then continue stepping up through 1.0 mg and 1.7 mg before reaching 2.4 mg, the standard maintenance dose studied in the STEP 1 trial published in the New England Journal of Medicine, which showed an average body-weight reduction of around 15% over 68 weeks. Each increase is reviewed clinically, because not everyone moves through the ladder at the same pace, some people hold a dose longer if tolerability warrants it.

Since April 2026, an additional step is available: a single 7.2 mg pen, approved by the MHRA, for patients who are established on 2.4 mg and where their prescriber judges a higher maintenance dose appropriate. This pen uses a different auto-dosing mechanism with a built-in covered needle and locks after use. Whether it's the right option for a particular patient is a clinical conversation, not a self-selection. You can read the full breakdown of Wegovy's approved dose steps if you want to understand what each stage typically involves.

If you're weighing up whether to begin treatment or wondering about the cost of a private prescription, our guide to accessing Wegovy through a regulated UK pharmacy covers what to expect from the process and what legitimate pricing looks like.

How a prescriber decides the pace of your titration

One of the questions our prescribers field most often is whether a patient can skip a dose step or double back to a lower one. The answer to both is: yes, with clinical input. If someone is struggling with persistent nausea at 0.5 mg, staying there longer rather than moving to 1.0 mg is a reasonable, evidence-consistent approach. The licensed schedule sets the framework; individual titration is a clinical judgement.

This is also why semaglutide cannot be safely self-prescribed or sourced without a proper assessment. The NHS guidance on semaglutide sets out the conditions under which it is and isn't suitable, including existing medical conditions and medicines that may interact with it. A prescriber checking your medication history before your first pen is dispatched isn't a formality, it's the part of the process that keeps the titration safe.

At nume, a real prescriber reads your consultation answers the same day you submit them. If you're clinically suitable and your order is placed before noon on a working day, your pen is dispatched the same day by DPD, arriving the next working day in plain, unbranded packaging, no markings on the box to indicate what's inside. That predictability matters when you're trying to keep a weekly injection on a consistent schedule. Speak to our prescribers to get started with a free consultation.